BTIG Starts Merrimack Pharmaceuticals (MACK) at Neutral

August 19, 2016 8:38 AM EDT
Get Alerts MACK Hot Sheet
Price: $3.05 --0%

Rating Summary:
    5 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 16 | New: 50
Trade MACK Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

BTIG initiated coverage on Merrimack Pharmaceuticals (NASDAQ: MACK) with a Neutral rating.

Analyst Ling Wang said, "MACK’s lead compound, ONIVYDE, was approved in the US in post-gemcitabine metastatic pancreatic cancer. While we see ONIVYDE as having paradigm shift potential and significant expansion opportunities, we expect the sales ramp-up to be gradual in the current indication. Although MACK has strong fundamentals, with major data from ONIVYDE in front-line pancreatic cancer, MM-302 and MM-121 won’t be available until 2017 or beyond; we expect MACK shares to be range-bound."

For an analyst ratings summary and ratings history on Merrimack Pharmaceuticals click here. For more ratings news on Merrimack Pharmaceuticals click here.

Shares of Merrimack Pharmaceuticals closed at $5.01 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Related Entities

BTIG

Add Your Comment